Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$52.95
$0.14(0.27%)
At close: 4:00 PM EDT
$52.95
$0.14(0.27%)
Day’s Range― - ―
52-Week Range$14.79 - $55.79
Previous Close$53
Volume368.77K
Average Volume (3M)1.68M
Market Cap
$3.77B
Enterprise Value$2.60B
Total Cash (Recent Filing)$452.40M
Total Debt (Recent Filing)$302.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 19, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding71,438,280
10 Day Avg. Volume622,646
30 Day Avg. Volume1,683,908
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.34K
Enterprise Value/Ebitda-26.38
Forecast
1Y Price Target
$67.88Price Target Upside28.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetNear-zero leverage and a materially enlarged equity base give Enliven durable financial flexibility to fund multi-year clinical programs, lower refinancing risk, and pursue partnerships or M&A. This structural strength supports R&D continuity and strategic optionality over the coming funding cycles.
De-risked Development Path For ELVN-001Robust Phase 1 efficacy/safety data together with explicit FDA alignment on dose and pivotal trial design materially de-risks ELVN-001's development. This durable regulatory clarity improves probability of success, informs resource allocation, and sets a clear pathway toward potential approval and commercialization.
Substantial Recent Financing CapacityA successful large equity raise meaningfully extends runway to advance pivotal trials and reduces near-term refinancing pressure. Access to public capital and institutional syndicate support provides long-term financing optionality to execute development milestones without immediate program cuts.
Bears Say
Pre-revenue With Widening LossesBeing a pre-revenue biotech with materially widening operating losses means Enliven cannot self-fund growth and is fully reliant on pipeline success. Persistent negative earnings concentrate value risk on clinical outcomes and create structural pressure on margins and strategic choices until commercialization.
Sustained Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow evidences ongoing cash burn tied to R&D. Even with recent capital, finite runway and variability in burn rates create a durable funding requirement that constrains strategic flexibility and increases the probability of future financing actions.
Dependence On Dilutive FinancingFrequent recourse to equity issuance and an expanded share authorization indicate structural dependence on dilutive financing to fund operations. Over time this can erode existing shareholders' ownership, complicate returns, and pressure management to prioritize capital raises over non-dilutive alternatives.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $55.79 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $3.77B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 20 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.064.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 71,438,280 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went up 1.142%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.88 (28.19% Upside)
$67.88 (28.19% Upside)
Blogger Sentiment
Bearish
ELVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 15.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.63%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biotechnology company focused on discovering and developing precision small-molecule therapies for patients with cancer. The company’s R&D efforts target genetically defined oncology indications, with a pipeline built around small-molecule kinase inhibitor programs designed to selectively inhibit cancer-driving targets while aiming to improve tolerability. Enliven operates in the biotechnology/pharmaceutical sector and is primarily engaged in research and clinical development rather than commercial product sales.
ELVN Stock 12 Month Forecast
Average Price Target
$67.88
▲(28.19% Upside)
Technical Analysis
Crispr Therapeutics AG
―
IDEAYA Biosciences
―
Legend Biotech
―
Relay Therapeutics
―
Tango Therapeutics
―
Ownership Overview
23.09% Insiders
14.26% Mutual Funds
0.64% Other Institutional Investors
52.25% Public Companies and
Individual Investors